ESMO WCGIC 2021 | Tiragolumab and atezolizumab in metastatic esophageal cancer

Zev A. Wainberg, MD, Msc, UCLA School of Medicine, Los Angeles, CA, provides an overview of the Phase Ib trial (NCT02794571) of the anti-TIGIT antibody tiragolumab in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory metastatic esophageal cancer. The current cohort of patients with esophageal cancer is a part of an expansion cohort in a trial assessing the preliminary safety and tolerability of tiragolumab and atezolizumab. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.